The phase 3 LUGANO trial investigating Duravyu for wet AMD did not meet its primary endpoint in the full dataset but showed positive results in treatment burden, supplement-free rates and anatomic control, according to a press release.
The randomized, double-masked, noninferiority LUGANO and LUCIA programs are investigating the safety and efficacy of Duravyu (vorolanib intravitreal insert, EyePoint Pharmaceuticals) vs. on-label aflibercept 2 mg as a treatment for wet age-related macular degeneration, with more than 900 patients enrolled across both trials. The primary endpoint looked at